Top

RADR®, or Response Algorithm for Drug Positioning & Rescue, is Lantern’s proprietary integrated data analytics, experimental biology, biotechnology, and machine-learning-based platform. RADR® is used primarily to predict the potential response patients will have to Lantern’s drugs and to other drugs that are being reviewed and analyzed by Lantern.

RADR® is also being used to help define and develop combination strategies among drugs in development and those that are approved for a range of oncology indications. RADR® uses transcriptome data, genomic data and drug sensitivity data from a wide range of curated sources that are continually being analyzed, monitored and updated. Our RADR® platform is core to our drug development approach for identifying the desired project candidates to in-license and develop.

Our RADR® platform is enabled through access to, and analysis of, a number of key datasets: (i) publicly available databases, (ii) data from commercial clinical studies and trials, and (iii) our proprietary data generated from ex vivo 3D tumor models specific to drug-tumor interactions. We incorporate automated supervised machine learning strategies along with big data analytics, statistics and systems biology to facilitate identification of new correlations of genetic biomarkers with drug activity.

The value of the platform architecture is derived from its validation through the analysis of over
8 billion oncology-specific clinical and preclinical data points, more than 144 drug-cancer interactions, and over 85,500 patient records from 17 databases, one of which is our internal database.

RADR® has now surpassed 8 billion data points, facilitating increased drug and cancer type-specific biomarker identification, the discovery of new indications, and the identification of additional drug candidates to build out our product pipeline towards advances in cancer therapy.

How It Works

Our artificial intelligence-based machine learning approach combines six automated modules that work sequentially to derive drug and tumor-specific complex biomarker panels. These six modules include: Data Ingest, Data Processing and Curation, Feature Selection, Prediction, Hypothesis Generation, Validation & Feedback, and Patient Stratification & Clinical Trial Design.

RADR® Workflow

Workflow Details

1. Data Ingest

Multi-omics data is received from large, public oncology data sources and private partner data sources. Lantern’s proprietary data is included here as well.

2. Data Preprocessing

This step includes data cleaning, transformation, normalization, and integration without compromising the original quality of data – datasets are reviewed by internal KOLs to ascertain relevance and quality. Data is standardized across patient samples, and connections are made that link preclinical models to patient samples and clinical data.

3. Feature Selection

RADR-A.I. performs proprietary gene filtering via biological, statistical and machine learning-based methods to extract relevant and significant biomarker and genomic features. Findings are benchmarked against published literature and data.

4. Prediction

An automated artificial intelligence algorithm uses filtered gene sets to build, tune and test the algorithm in an iterative process that selects an optimal model having high testing accuracy. This module will also generate 50-200 drug tumor-specific candidate biomarkers.

5. Hypothesis Generation, Validation, and Feedback

Data mining and Machine Learning pipelines lead to hypothesis generation, which guides additional preclinical research in the lab, which produces more data. This data can be used to validate hypotheses, which are then added back to the system, thus improving the accuracy of our predictions.

6. Patient Stratification and Clinical Trial Design

Our final, tuned model uses available patient data on candidate biomarkers to predict medical drug response and stratifies patients as responders, partial responders, or non-responders. Response prediction informs both companion diagnostic (CDx) development and clinical trial design for advancements in experimental medicine.

1. Data Ingest

Multi-omics data is received from large, public oncology data sources and private partner data sources. Lantern’s proprietary data is included here as well.

2. Data Processing & Curation

This step includes data cleaning, transformation, normalization, and integration without compromising the original quality of data – datasets are reviewed by internal KOLs to ascertain relevance and quality. Data is standardized across patient samples, and connections are made that link preclinical models to patient samples and clinical data.

3. Feature Selection

RADR® -A.I. performs proprietary gene filtering via biological, statistical and machine learning-based methods to extract biologically relevant and statistically significant biomarkers and genomic features. Findings are benchmarked against published literature and data.

4. Prediction

An automated artificial intelligence algorithm uses filtered gene sets to build, tune and test the algorithm in an iterative process that selects an optimal model having highest testing accuracy. This module will also generate 50-200 drug tumor-specific candidate biomarkers.

5. Hypothesis Generation, Validation, and Feedback

Data mining and Machine Learning pipelines lead to hypothesis generation, which guides additional preclinical research in the lab, which produces more data. This data can be used to validate hypotheses, which are then added back to the system, thus improving the accuracy of our predictions.

6. Patient Stratification and Clinical Trial Design

Our final, tuned model uses available patient data on candidate biomarkers to predict medical drug response and stratifies patients as responders, partial responders, or non-responders. Response prediction informs both companion diagnostic (CDx) development and clinical trial design for advancements in experimental medicine.

X
Thank you! Here's your Whitepaper
Oops! Something went wrong while submitting the form.

Learn how we are advancing oncology drug development

Download Our Whitepaper
"We are in the golden age of A.I. where we are able to significantly impact the speed and precision at which we develop new drugs."
Panna Sharma
PRESIDENT & CEO, LANTERN PHARMA